Victory Capital Management, Inc. recently announced the acquisition of new stake in Equillium Inc. (NASDAQ:EQ). The institutional investor has increased its shareholding in the Healthcare company by 2.07% to 3.65 million shares with purchase of 73873.0 shares. This fresh investment now brings its stake to 10.63% valued currently at $3.87 million. In addition, DCF Capital LLC raised its holdings by 0.12 million to 0.23 million shares. And Goldman Sachs Asset Management In has lifted its position by 59.14% or 21298.0 shares – to 57310.0 shares.
With over 0.43 million Equillium Inc. (EQ) shares trading Friday and a closing price of $1.10 on the day, the dollar volume was approximately $0.47 million. The shares have shown a negative half year performance of -51.11% and its price on 01/13/23 lost nearly -6.78%. Currently, there are 34.35M common shares owned by the public and among those 23.39M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for EQ have a consensus price objective of $11.20. The analysts have set the share’s price value over the next 12 months at a high of $20.00 and a low of $4.00. The average price target is 91.08% above its recent price level and an upside to the estimated low will see the stock gain 72.5% over that period. But an upside of 94.5% will see the stock hit the forecast high price target while median target price for the stock is $12.00.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 20,000 shares.
The top 3 mutual fund holders in Equillium Inc. are Victory RS Small Cap Growth Fund, USAA Science & Technology Fund, and FTIF SICAV – Biotechnology Discov. Victory RS Small Cap Growth Fund owns 1.63 million shares of the company’s stock, all valued at over $1.73 million. The company bought an additional 12100.0 shares recently to bring their total holdings to about 4.75% of the shares outstanding. USAA Science & Technology Fund bought 0.17 million shares to see its total holdings expand to 0.97 million shares valued at over $1.03 million and representing 2.83% of the shares outstanding. FTIF SICAV – Biotechnology Discov now owns shares totaling to 1.75% of the shares outstanding.
Shares of Equillium Inc. (NASDAQ: EQ) opened at $1.23, up $0.05 from a prior closing price of $1.18. However, the script later moved the day high at 1.2100, down -6.78%. The company’s stock has a 5-day price change of -4.35% and -42.11% over the past three months. EQ shares are trading 3.77% year to date (YTD), with the 12-month market performance down to -69.44% lower. It has a 12-month low price of $0.79 and touched a high of $4.38 over the same period. EQ has an average intraday trading volume of 57.56K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.75%, -22.47%, and -48.59% respectively.
Institutional ownership of Equillium Inc. (NASDAQ: EQ) shares accounts for 38.80% of the company’s 34.35M shares outstanding. Mutual fund holders own 18.86%, while other institutional holders and individual stakeholders account for 32.27% and 1.98% respectively.
It has a market capitalization of $40.50M and a beta (3y monthly) value of 1.23. The earnings-per-share (ttm) stands at -$2.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.70% over the week and 11.33% over the month.
Analysts forecast that Equillium Inc. (EQ) will achieve an EPS of -$0.38 for the current quarter, -$0.36 for the next quarter and -$1.34 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.41 while analysts give the company a high EPS estimate of -$0.34. Comparatively, EPS for the current quarter was -$0.35 a year ago. Earnings per share for the fiscal year are expected to increase by 7.40%, and 23.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Equillium Inc. (EQ) as a “Moderate Buy” at a consensus score of 2.50. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the EQ, a number of firms have released research notes about the stock. Stifel stated their Buy rating for the stock in a research note on October 29, 2021, with the firm’s price target at $12. Cantor Fitzgerald coverage for the Equillium Inc. (EQ) stock in a research note released on September 15, 2021 offered a Overweight rating with a price target of $14. H.C. Wainwright was of a view on July 14, 2020 that the stock is Buy, while Stifel gave the stock Buy rating on July 10, 2020, issuing a price target of $22- $10. SVB Leerink on their part issued Outperform rating on February 22, 2019.